KARL Vance SITZ
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Allergy & Immunology
- Where
- Bryant, AR
- NPI
- 1518959691
- Received
- $22,065 in 315 records, 2019 to 2025 ($19,392 general, $2,673 research)
- As principal investigator
- $1,845,457 of research payments to others in 322 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 32 | $1,714 |
| 2024 | General payment | 14 | $4,115 |
| 2024 | Research payment | 9 | $1,709 |
| 2023 | General payment | 67 | $6,968 |
| 2023 | Research payment | 2 | $963 |
| 2022 | General payment | 47 | $812 |
| 2021 | General payment | 55 | $865 |
| 2020 | General payment | 37 | $435 |
| 2019 | General payment | 52 | $4,479 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| CSL Behring | 33 | $11,142 | 2019–2024 |
| BioCryst Pharmaceuticals, Inc. | 9 | $3,275 | 2019–2020 |
| GlaxoSmithKline, LLC. | 100 | $2,811 | 2019–2024 |
| Novartis Pharmaceuticals Corporation | 31 | $1,975 | 2019–2025 |
| Regeneron Healthcare Solutions, Inc. | 25 | $559 | 2019–2025 |
| AstraZeneca Pharmaceuticals LP | 19 | $441 | 2019–2025 |
| GENZYME CORPORATION | 18 | $390 | 2019–2024 |
| Grifols USA, LLC | 16 | $368 | 2019–2025 |
| Genentech USA, Inc. | 13 | $205 | 2019–2025 |
| kaleo, Inc. | 10 | $175 | 2019–2023 |
| Octapharma USA, Inc. | 2 | $114 | 2019 |
| BioCryst US Sales Co., LLC | 7 | $112 | 2021–2023 |
| Pharming Healthcare, Inc. | 5 | $94 | 2019–2023 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $70 | 2020–2022 |
| PFIZER INC. | 5 | $68 | 2019–2022 |
| Teva Pharmaceuticals USA, Inc. | 4 | $51 | 2019–2021 |
| Shire North American Group Inc | 3 | $49 | 2019 |
| ADMA BioManufacturing LLC | 2 | $32 | 2021–2025 |
| Optinose US, Inc. | 2 | $25 | 2019 |
| ALK-Abello, Inc | 1 | $18 | 2023 |
| Mylan Specialty L.P. | 1 | $16 | 2019 |
| Merck Sharp & Dohme LLC | 1 | $15 | 2023 |
| Hikma Pharmaceuticals USA | 1 | $14 | 2023 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $13 | 2022 |
| LEO Pharma Inc. | 1 | $12 | 2023 |
| Amgen Inc. | 1 | $11 | 2022 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 15 | $9,896 |
| Food and Beverage | 280 | $5,303 |
| Research payment | 11 | $2,673 |
| Honoraria | 1 | $2,100 |
| Travel and Lodging | 6 | $2,049 |
| Education | 1 | $24 |
| Consulting Fee | 1 | $19 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-17 | Novartis Pharmaceuticals Corporation | $25 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-12-10 | Grifols USA, LLC | $19 | Food and Beverage | In-kind items and services | Xembify Biological, Immunology and Neurology | 2025 | |
| 2025-12-08 | Genentech USA, Inc. | $20 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2025 | |
| 2025-11-19 | Novartis Pharmaceuticals Corporation | $11 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-11-10 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-10-29 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-10-16 | Novartis Pharmaceuticals Corporation | $11 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-10-15 | Grifols USA, LLC | $21 | Food and Beverage | In-kind items and services | Xembify Biological, Immunology and Neurology | 2025 | |
| 2025-10-13 | Novartis Pharmaceuticals Corporation | $15 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-10-03 | Novartis Pharmaceuticals Corporation | $7 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-09-26 | Novartis Pharmaceuticals Corporation | $646 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-09-26 | Novartis Pharmaceuticals Corporation | $219 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-26 | Novartis Pharmaceuticals Corporation | $198 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-09-25 | Novartis Pharmaceuticals Corporation | $139 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-17 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-04 | Novartis Pharmaceuticals Corporation | $14 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-27 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-11 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-30 | Novartis Pharmaceuticals Corporation | $15 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-14 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-30 | Regeneron Healthcare Solutions, Inc. | $15 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-06-25 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-11 | ADMA BioManufacturing LLC | $19 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-04 | Genentech USA, Inc. | $19 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2025 | |
| 2025-05-19 | Novartis Pharmaceuticals Corporation | $20 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-14 | Grifols USA, LLC | $20 | Food and Beverage | In-kind items and services | Xembify Biological, Immunology and Neurology | 2025 | |
| 2025-04-24 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-04-23 | Regeneron Healthcare Solutions, Inc. | $22 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-03-31 | AstraZeneca Pharmaceuticals LP | $21 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-10 | Genentech USA, Inc. | $15 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2025 | |
| 2025-02-12 | Grifols USA, LLC | $30 | Food and Beverage | In-kind items and services | Xembify Biological, Immunology and Neurology | 2025 | |
| 2025-02-10 | Genentech USA, Inc. | $14 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2025 | |
| 2024-12-19 | CSL Behring | $354 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2024 | ||
| 2024-12-17 | CSL Behring | $2,645 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2024 | ||
| 2024-12-04 | GENZYME CORPORATION | $19 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-11-20 | CSL Behring | $20 | Food and Beverage | In-kind items and services | Hizentra Biological, Immunology | 2024 | |
| 2024-11-04 | Genentech USA, Inc. | $15 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2024 | |
| 2024-10-23 | Grifols USA, LLC | $24 | Food and Beverage | In-kind items and services | Xembify Biological, Immunology and Neurology | 2024 | |
| 2024-08-22 | Grifols USA, LLC | $26 | Food and Beverage | In-kind items and services | Xembify Biological, Immunology and Neurology | 2024 | |
| 2024-06-28 | CSL Behring | $355 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2024 | ||
| 2024-06-11 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2024 | |
| 2024-05-22 | GlaxoSmithKline, LLC. | $57 | Research payment | Cash or cash equivalent | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-04-25 | GlaxoSmithKline, LLC. | $937 | Research payment | In-kind items and services | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-04-25 | GlaxoSmithKline, LLC. | $268 | Research payment | In-kind items and services | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-04-25 | GlaxoSmithKline, LLC. | $181 | Research payment | In-kind items and services | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-04-25 | GlaxoSmithKline, LLC. | $100 | Research payment | In-kind items and services | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-04-25 | GlaxoSmithKline, LLC. | $90 | Research payment | In-kind items and services | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-04-25 | GlaxoSmithKline, LLC. | $35 | Research payment | In-kind items and services | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-04-25 | GlaxoSmithKline, LLC. | $20 | Research payment | In-kind items and services | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-04-25 | GlaxoSmithKline, LLC. | $16 | Research payment | In-kind items and services | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 | |
| 2024-04-02 | Regeneron Healthcare Solutions, Inc. | $26 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2024 | |
| 2024-03-15 | Regeneron Healthcare Solutions, Inc. | $26 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2024 | |
| 2024-02-22 | Grifols USA, LLC | $25 | Food and Beverage | In-kind items and services | Xembify Biological, Immunology and Neurology | 2024 | |
| 2024-02-14 | Regeneron Healthcare Solutions, Inc. | $17 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2024 | |
| 2024-02-12 | CSL Behring | $542 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2024 | ||
| 2023-12-08 | CSL Behring | $657 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2023 | ||
| 2023-11-28 | CSL Behring | $18 | Food and Beverage | In-kind items and services | Hizentra Biological, Immunology | 2023 | |
| 2023-11-21 | CSL Behring | $2,234 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2023 | ||
| 2023-11-01 | GENZYME CORPORATION | $26 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2023 | |
| 2023-10-18 | Grifols USA, LLC | $24 | Food and Beverage | In-kind items and services | Xembify Biological, Immunology and Neurology | 2023 | |
| 2023-10-12 | CSL Behring | $182 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2023 | ||
| 2023-10-10 | GlaxoSmithKline, LLC. | $9 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-10-04 | GENZYME CORPORATION | $24 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2023 | |
| 2023-10-03 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2023 | |
| 2023-09-26 | GlaxoSmithKline, LLC. | $19 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-09-13 | GlaxoSmithKline, LLC. | $18 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2023 | |
| 2023-09-11 | GlaxoSmithKline, LLC. | $12 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-09-06 | GENZYME CORPORATION | $27 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2023 | |
| 2023-09-06 | CSL Behring | $14 | Food and Beverage | In-kind items and services | Hizentra Biological, Immunology | 2023 | |
| 2023-08-31 | GlaxoSmithKline, LLC. | $10 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-08-30 | Regeneron Healthcare Solutions, Inc. | $19 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2023 | |
| 2023-08-30 | LEO Pharma Inc. | $12 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2023 | |
| 2023-08-24 | CSL Behring | $90 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2023 | ||
| 2023-08-22 | GlaxoSmithKline, LLC. | $18 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2023 | |
| 2023-08-21 | Merck Sharp & Dohme LLC | $15 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-08-09 | BioCryst US Sales Co., LLC | $21 | Food and Beverage | In-kind items and services | ORLADEYO Drug, Immunology | 2023 | |
| 2023-08-02 | Grifols USA, LLC | $23 | Food and Beverage | In-kind items and services | Xembify Biological, Immunology and Neurology | 2023 | |
| 2023-08-02 | CSL Behring | $17 | Food and Beverage | In-kind items and services | Hizentra Biological, Immunology | 2023 | |
| 2023-07-31 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2023 | |
| 2023-07-27 | GlaxoSmithKline, LLC. | $17 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-07-26 | AstraZeneca Pharmaceuticals LP | $25 | Food and Beverage (3 payments) | In-kind items and services | BREZTRI Drug, Respiratory | 2023 | |
| 2023-07-24 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2023 | |
| 2023-07-21 | CSL Behring | $195 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2023 | ||
| 2023-07-19 | GENZYME CORPORATION | $20 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2023 | |
| 2023-07-17 | GlaxoSmithKline, LLC. | $7 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-06-29 | Regeneron Healthcare Solutions, Inc. | $25 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2023 | |
| 2023-06-21 | ALK-Abello, Inc | $18 | Food and Beverage | In-kind items and services | Grastek Drug, Allergy and Immunology | 2023 | |
| 2023-06-14 | GENZYME CORPORATION | $21 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2023 | |
| 2023-06-13 | CSL Behring | $453 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2023 | ||
| 2023-06-13 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-06-13 | GlaxoSmithKline, LLC. | $2 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2023 | |
| 2023-06-07 | Grifols USA, LLC | $18 | Food and Beverage | In-kind items and services | Xembify Biological, Immunology and Neurology | 2023 | |
| 2023-06-06 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2023 | |
| 2023-06-01 | Regeneron Healthcare Solutions, Inc. | $21 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2023 | |
| 2023-05-31 | CSL Behring | $79 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2023 | ||
| 2023-05-17 | CSL Behring | $711 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2023 | ||
| 2023-05-17 | kaleo, Inc. | $19 | Food and Beverage | In-kind items and services | AUVI-Q Drug, Allergy | 2023 | |
| 2023-05-16 | CSL Behring | $299 | Research payment | In-kind items and services | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment | 2023 | |
| 2023-05-15 | GlaxoSmithKline, LLC. | $9 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-05-10 | GENZYME CORPORATION | $24 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2023 | |
| 2023-05-09 | AstraZeneca Pharmaceuticals LP | $12 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2023 | |
| 2023-05-04 | CSL Behring | $664 | Research payment | In-kind items and services | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment | 2023 | |
| 2023-04-24 | CSL Behring | $706 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2023 | ||
| 2023-04-13 | Grifols USA, LLC | $22 | Food and Beverage | In-kind items and services | Xembify Biological, Immunology and Neurology | 2023 | |
| 2023-04-05 | Hikma Pharmaceuticals USA | $14 | Food and Beverage | In-kind items and services | Ryaltris Drug, Pulmonary/Respiratory Diseases | 2023 | |
| 2023-04-05 | GlaxoSmithKline, LLC. | $10 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-03-29 | Regeneron Healthcare Solutions, Inc. | $22 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2023 | |
| 2023-03-24 | CSL Behring | $385 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2023 | ||
| 2023-03-17 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2023 | |
| 2023-03-15 | GENZYME CORPORATION | $22 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2023 | |
| 2023-03-06 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-03-03 | GlaxoSmithKline, LLC. | $8 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2023 | |
| 2023-02-27 | GlaxoSmithKline, LLC. | $18 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-02-24 | CSL Behring | $301 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2023 | ||
| 2023-02-22 | Grifols USA, LLC | $26 | Food and Beverage | In-kind items and services | Xembify Biological, Immunology and Neurology | 2023 | |
| 2023-02-20 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2023 | |
| 2023-02-15 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-02-09 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2023 | |
| 2023-01-30 | GENZYME CORPORATION | $23 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2023 | |
| 2023-01-24 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-01-19 | Regeneron Healthcare Solutions, Inc. | $25 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2023 | |
| 2023-01-12 | GlaxoSmithKline, LLC. | $8 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2023 | |
| 2023-01-11 | GlaxoSmithKline, LLC. | $0 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2023 | |
| 2023-01-10 | Pharming Healthcare, Inc. | $15 | Food and Beverage | In-kind items and services | RUCONEST Biological, BIOLOGIC | 2023 | |
| 2022-12-15 | Grifols USA, LLC | $20 | Food and Beverage | In-kind items and services | Xembify Biological, Immunology and Neurology | 2022 | |
| 2022-12-10 | GlaxoSmithKline, LLC. | $17 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2022 | |
| 2022-12-05 | GlaxoSmithKline, LLC. | $8 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2022 | |
| 2022-11-30 | kaleo, Inc. | $12 | Food and Beverage | In-kind items and services | AUVI-Q Drug, Allergy | 2022 | |
| 2022-11-21 | Regeneron Healthcare Solutions, Inc. | $23 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2022 | |
| 2022-11-21 | GlaxoSmithKline, LLC. | $8 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2022 | |
| 2022-11-16 | Grifols USA, LLC | $21 | Food and Beverage | In-kind items and services | Xembify Biological, Immunology and Neurology | 2022 | |
| 2022-11-09 | GENZYME CORPORATION | $26 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2022 | |
| 2022-11-02 | GlaxoSmithKline, LLC. | $10 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2022 | |
| 2022-10-26 | Regeneron Healthcare Solutions, Inc. | $29 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2022 | |
| 2022-10-26 | GlaxoSmithKline, LLC. | $10 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2022 | |
| 2022-10-18 | BioCryst US Sales Co., LLC | $15 | Food and Beverage | In-kind items and services | ORLADEYO Drug, Immunology | 2022 | |
| 2022-09-21 | GlaxoSmithKline, LLC. | $11 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2022 | |
| 2022-09-15 | Regeneron Healthcare Solutions, Inc. | $24 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2022 | |
| 2022-09-14 | CSL Behring | $12 | Food and Beverage | In-kind items and services | Hizentra Biological, Immunology | 2022 | |
| 2022-08-31 | GlaxoSmithKline, LLC. | $10 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2022 | |
| 2022-08-30 | Takeda Pharmaceuticals U.S.A., Inc. | $16 | Food and Beverage | In-kind items and services | TAKHZYRO Biological, GENETIC DISEASE | 2022 | |
| 2022-08-24 | Regeneron Healthcare Solutions, Inc. | $28 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2022 | |
| 2022-08-24 | CSL Behring | $13 | Food and Beverage | In-kind items and services | Hizentra Biological, Immunology | 2022 | |
| 2022-08-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13 | Food and Beverage | In-kind items and services | STIOLTO RESPIMAT Drug, RESPIRATORY | 2022 | |
| 2022-08-10 | GENZYME CORPORATION | $26 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2022 | |
| 2022-07-21 | Amgen Inc. | $11 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Inflammation | 2022 | |
| 2022-07-06 | GENZYME CORPORATION | $26 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2022 | |
| 2022-06-30 | AstraZeneca Pharmaceuticals LP | $21 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-06-29 | GlaxoSmithKline, LLC. | $14 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2022 | |
| 2022-06-27 | BioCryst US Sales Co., LLC | $16 | Food and Beverage | In-kind items and services | ORLADEYO Drug, Immunology | 2022 | |
| 2022-06-22 | Regeneron Healthcare Solutions, Inc. | $25 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2022 | |
| 2022-06-15 | Grifols USA, LLC | $25 | Food and Beverage | In-kind items and services | Xembify Biological, Immunology and Neurology | 2022 | |
| 2022-06-08 | GENZYME CORPORATION | $24 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2022 | |
| 2022-06-01 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2022 | |
| 2022-05-25 | Novartis Pharmaceuticals Corporation | $20 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-05-23 | GlaxoSmithKline, LLC. | $8 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2022 | |
| 2022-05-11 | GlaxoSmithKline, LLC. | $10 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2022 | |
| 2022-05-09 | AstraZeneca Pharmaceuticals LP | $12 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2022 | |
| 2022-05-04 | Pharming Healthcare, Inc. | $25 | Food and Beverage | In-kind items and services | RUCONEST Biological, BIOLOGIC | 2022 | |
| 2022-04-25 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | OCTAGAM IMMUNE GLOBULIN (HUMAN) Drug, IMMUNOLOGY | 2022 | |
| 2022-04-21 | GlaxoSmithKline, LLC. | $10 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2022 | |
| 2022-04-20 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-04-13 | Regeneron Healthcare Solutions, Inc. | $26 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2022 | |
| 2022-03-23 | AstraZeneca Pharmaceuticals LP | $12 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2022 | |
| 2022-03-21 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | EUCRISA Drug, DERMATOLOGY | 2022 | |
| 2022-03-01 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2022 | |
| 2022-02-22 | Novartis Pharmaceuticals Corporation | $14 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-02-17 | kaleo, Inc. | $16 | Food and Beverage | In-kind items and services | AUVI-Q Drug, Allergy | 2022 | |
| 2022-02-15 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2022 | |
| 2022-01-19 | Novartis Pharmaceuticals Corporation | $15 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-01-11 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2022 | |
| 2021-12-01 | Regeneron Healthcare Solutions, Inc. | $19 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2021 | |
| 2021-12-01 | GlaxoSmithKline, LLC. | $19 | Food and Beverage | In-kind items and services | ANORO ELLIPTA Drug, RESPIRATORY | 2021 | |
| 2021-11-29 | Novartis Pharmaceuticals Corporation | $15 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-11-22 | GENZYME CORPORATION | $23 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2021 | |
| 2021-11-17 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2021 | |
| 2021-11-16 | GlaxoSmithKline, LLC. | $11 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2021 | |
| 2021-11-15 | Genentech USA, Inc. | $15 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2021 | |
| 2021-11-09 | GlaxoSmithKline, LLC. | $14 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2021 | |
| 2021-11-03 | Regeneron Healthcare Solutions, Inc. | $15 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2021 | |
| 2021-11-02 | kaleo, Inc. | $20 | Food and Beverage | In-kind items and services | AUVI-Q Drug, ALLERGY | 2021 | |
| 2021-10-26 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2021 | |
| 2021-10-26 | GlaxoSmithKline, LLC. | $1 | Food and Beverage | In-kind items and services | ANORO ELLIPTA Drug, RESPIRATORY | 2021 | |
| 2021-10-12 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2021 | |
| 2021-10-11 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2021 | |
| 2021-10-05 | BioCryst US Sales Co., LLC | $14 | Food and Beverage | In-kind items and services | Orladeyo Drug, Immunology | 2021 | |
| 2021-09-22 | Teva Pharmaceuticals USA, Inc. | $14 | Food and Beverage | In-kind items and services | AirDuo Digihaler Drug, Respiratory | 2021 | |
| 2021-09-21 | kaleo, Inc. | $17 | Food and Beverage | In-kind items and services | AUVI-Q Drug, ALLERGY | 2021 | |
| 2021-09-15 | GlaxoSmithKline, LLC. | $12 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2021 | |
| 2021-09-15 | GlaxoSmithKline, LLC. | $11 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2021 | |
| 2021-09-06 | GlaxoSmithKline, LLC. | $11 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2021 | |
| 2021-08-25 | GlaxoSmithKline, LLC. | $12 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2021 | |
| 2021-08-16 | Regeneron Healthcare Solutions, Inc. | $17 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2021 | |
| 2021-08-14 | GlaxoSmithKline, LLC. | $3 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2021 | |
| 2021-08-04 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2021 | |
| 2021-07-27 | Takeda Pharmaceuticals U.S.A., Inc. | $21 | Food and Beverage | In-kind items and services | TAKHZYRO Biological, GENETIC DISEASE | 2021 | |
| 2021-07-22 | CSL Behring | $17 | Food and Beverage | In-kind items and services | Haegarda Biological, Immunology | 2021 | |
| 2021-07-21 | GlaxoSmithKline, LLC. | $11 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2021 | |
| 2021-07-19 | GlaxoSmithKline, LLC. | $10 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2021 | |
| 2021-06-28 | GlaxoSmithKline, LLC. | $12 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2021 |
The latest 200 records of 315.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-19 | GlaxoSmithKline, LLC. | ACURO RESEARCH | $1,640 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-12-15 | CSL Behring | ACURO RESEARCH INC | $621 | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment | 2025 |
| 2025-12-11 | GlaxoSmithKline, LLC. | ACURO RESEARCH | $431 | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | 2025 |
| 2025-11-25 | PFIZER INC. | ACURO RESEARCH INC | $518 | A PHASE 2B RANDOMIZED DOUBLEBLIND 12WEEK PLACEBOCONTROLLED STUDY WITH A 12WEEK DOUBLEBLIND EXTENSION PERIOD TO EVALUAT | 2025 |
| 2025-11-25 | GlaxoSmithKline, LLC. | ACURO RESEARCH | $5,339 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-11-25 | PFIZER INC. | ACURO RESEARCH INC | $1,687 | A PHASE 2B RANDOMIZED DOUBLEBLIND 12WEEK PLACEBOCONTROLLED STUDY WITH A 12WEEK DOUBLEBLIND EXTENSION PERIOD TO EVALUAT | 2025 |
| 2025-11-14 | GlaxoSmithKline, LLC. | ACURO RESEARCH | $16,853 | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 |
| 2025-10-23 | GlaxoSmithKline, LLC. | ACURO RESEARCH | $6,912 | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | 2025 |
| 2025-10-22 | CSL Behring | ACURO RESEARCH INC | $1,974 | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment | 2025 |
| 2025-10-17 | GlaxoSmithKline, LLC. | ACURO RESEARCH | $2,111 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-10-14 | GlaxoSmithKline, LLC. | ACURO RESEARCH | $2,165 | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | 2025 |
| 2025-10-08 | Novartis Pharmaceuticals Corporation | ACURO RESEARCH INC | $146 | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared | 2025 |
| 2025-10-02 | GlaxoSmithKline, LLC. | ACURO RESEARCH | $6,024 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-09-03 | GlaxoSmithKline, LLC. | ACURO RESEARCH | $4,558 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-08-27 | GlaxoSmithKline, LLC. | ACURO RESEARCH | $3,282 | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | 2025 |
| 2025-08-04 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $7 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-08-04 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $7 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-08-04 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $7 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-08-04 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $24 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-08-04 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $16 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-08-04 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $11 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-08-04 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $57 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-08-04 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $3 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-08-04 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $7 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-08-04 | GlaxoSmithKline, LLC. | ACURO RESEARCH | $5,234 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-07-23 | GlaxoSmithKline, LLC. | ACURO RESEARCH | $25,164 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-07-15 | Novartis Pharmaceuticals Corporation | ACURO RESEARCH INC | $23,054 | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared | 2025 |
| 2025-06-26 | CSL Behring | ACURO RESEARCH INC | $117 | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment | 2025 |
| 2025-06-20 | GlaxoSmithKline, LLC. | ACURO RESEARCH | $5,006 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-05-21 | GlaxoSmithKline, LLC. | ACURO RESEARCH | $5,991 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-05-16 | Teva Pharmaceuticals USA, Inc. | ACURO RESEARCH INC | $10,200 | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate | 2025 |
| 2025-05-12 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $1,404 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-04-23 | GlaxoSmithKline, LLC. | ACURO RESEARCH | $18,054 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-04-22 | Teva Pharmaceuticals USA, Inc. | ACURO RESEARCH INC | $179 | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate | 2025 |
| 2025-04-17 | GlaxoSmithKline, LLC. | ACURO RESEARCH | $8,722 | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | 2025 |
| 2025-04-14 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $1,404 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-04-02 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $22 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-04-02 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $22 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-04-02 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $22 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-04-02 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $22 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-04-02 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $22 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-04-02 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $22 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-04-02 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $11 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-04-02 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $173 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-04-02 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $22 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-04-02 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $74 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-04-02 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $173 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-04-02 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $5 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-04-02 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $57 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-04-02 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $16 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-04-02 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $6 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-04-02 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $22 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-04-02 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $20 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-04-02 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $57 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-04-02 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $74 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-04-02 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $22 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-03-25 | AstraZeneca Pharmaceuticals LP | LITTLE ROCK ALLERGY AND ASTHMA CLINIC, PA | $9,007 | The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do no | 2025 |
| 2025-03-19 | AstraZeneca Pharmaceuticals LP | ACURO RESEARCH, LNC | $19,682 | A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic | 2025 |
| 2025-03-14 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $1,803 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-03-14 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $1,573 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-03-14 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $983 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-03-14 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $2,009 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-03-14 | GlaxoSmithKline, LLC. | ACURO RESEARCH | $52,993 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-03-11 | Novartis Pharmaceuticals Corporation | LITTLE ROCK ALLERGY ASTHMA CLINIC PA | $18,225 | A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-t | 2025 |
| 2025-02-27 | Novartis Pharmaceuticals Corporation | LITTLE ROCK ALLERGY ASTHMA CLINIC PA | $2,794 | A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to inves | 2025 |
| 2025-02-06 | GlaxoSmithKline, LLC. | ACURO RESEARCH | $4,251 | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | 2025 |
| 2025-02-06 | GlaxoSmithKline, LLC. | ACURO RESEARCH | $1,697 | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | 2025 |
| 2025-02-06 | GlaxoSmithKline, LLC. | ACURO RESEARCH | $8,315 | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | 2025 |
| 2025-01-30 | GlaxoSmithKline, LLC. | ACURO RESEARCH | $1,210 | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | 2025 |
| 2025-01-30 | GlaxoSmithKline, LLC. | ACURO RESEARCH | $2,420 | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | 2025 |
| 2025-01-14 | CSL Behring | ACURO RESEARCH INC | $115 | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment | 2025 |
| 2025-01-02 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $73 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-01-02 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $272 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2025 |
| 2025-01-01 | Novartis Pharmaceuticals Corporation | ACURO RESEARCH | $25,645 | A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-t | 2025 |
| 2025-01-01 | Novartis Pharmaceuticals Corporation | ACURO RESEARCH | $15,430 | A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to inves | 2025 |
| 2024-12-13 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $2,119 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2024 |
| 2024-12-13 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $1,384 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2024 |
| 2024-12-13 | Incyte Corporation | LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC | $2,119 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Par | 2024 |
| 2024-12-11 | CSL Behring | Little RockAllergy & Asthma Clinical Research Center | $2,037 | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment | 2024 |
| 2024-11-25 | CSL Behring | Little RockAllergy & Asthma Clinical Research Center | $9,467 | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment | 2024 |
| 2024-11-22 | CSL Behring | Little RockAllergy & Asthma Clinical Research Center | $621 | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | LITTLE ROCK ALLERGY AND ASTHMA CLINIC PA | $1,578 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | LITTLE ROCK ALLERGY AND ASTHMA CLINIC PA | $505 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | LITTLE ROCK ALLERGY AND ASTHMA CLINIC PA | $434 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | LITTLE ROCK ALLERGY AND ASTHMA CLINIC PA | $1,569 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | LITTLE ROCK ALLERGY AND ASTHMA CLINIC PA | $434 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | LITTLE ROCK ALLERGY AND ASTHMA CLINIC PA | $859 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | LITTLE ROCK ALLERGY AND ASTHMA CLINIC PA | $1,353 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | LITTLE ROCK ALLERGY AND ASTHMA CLINIC PA | $434 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | LITTLE ROCK ALLERGY AND ASTHMA CLINIC PA | $434 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | LITTLE ROCK ALLERGY AND ASTHMA CLINIC PA | $1,838 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | LITTLE ROCK ALLERGY AND ASTHMA CLINIC PA | $1,353 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | LITTLE ROCK ALLERGY AND ASTHMA CLINIC PA | $434 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | LITTLE ROCK ALLERGY AND ASTHMA CLINIC PA | $1,875 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | LITTLE ROCK ALLERGY AND ASTHMA CLINIC PA | $859 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | LITTLE ROCK ALLERGY AND ASTHMA CLINIC PA | $810 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | LITTLE ROCK ALLERGY AND ASTHMA CLINIC PA | $1,609 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | LITTLE ROCK ALLERGY AND ASTHMA CLINIC PA | $505 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | LITTLE ROCK ALLERGY AND ASTHMA CLINIC PA | $1,281 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | LITTLE ROCK ALLERGY AND ASTHMA CLINIC PA | $2,989 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Bryant, AR, county Saline County, AR, state Arkansas; placed by its city name.
| Measure | Place (city or town) Bryant, AR | County Saline County, AR | State Arkansas |
|---|---|---|---|
| Population B01003 | 21,504 | 127,479 | 3,049,391 |
| Population, 2020 census P1 | 20,663 | 123,416 | 3,011,524 |
| Median age B01002 | 35.8 | 40.5 | 38.5 |
| Under 18 B01001 | 28.7% | 23.3% | 23.1% |
| 65 and over B01001 | 13.5% | 18.4% | 17.6% |
| Households B11001 | 8,262 | 50,203 | 1,205,987 |
| Foreign born B05002 | 3.9% | 4.2% | 5.4% |
| Median household income B19013 | $83,024 | $79,046 | $60,773 |
| Median family income B19113 | $99,639 | $96,365 | $76,968 |
| Per capita income B19301 | $40,257 | $38,887 | $34,225 |
| Poverty rate B17001 | 5.6% | 8.8% | 16.0% |
| Unemployment rate B23025 | 2.6% | 3.9% | 4.9% |
| Civilian labor force B23025 | 10,988 | 63,121 | 1,411,269 |
| Mean commute (minutes) B08013 | 22.8 | 25.3 | 22.5 |
| Bachelor's degree or higher B15003 | 37.7% | 29.4% | 25.7% |
| Housing units B25001 | 8,503 | 52,934 | 1,394,673 |
| Owner-occupied B25003 | 71.1% | 78.2% | 66.4% |
| Renters B25003 | 28.9% | 21.8% | 33.6% |
| Median home value B25077 | $223,200 | $221,200 | $188,000 |
| Median gross rent B25064 | $993 | $1,033 | $947 |
| White, not Hispanic B03002 | 70.7% | 78.3% | 67.4% |
| Black B03002 | 14.9% | 9.3% | 14.6% |
| Hispanic or Latino B03002 | 7.6% | 7.3% | 9.0% |
| Asian B03002 | 2.1% | 1.0% | 1.6% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.3% |
Economy now FRED unemployment 3.9% in Sep 2026 (4.2% a year earlier); per capita personal income $61,697 in 2025, up 31% in five years (+5.2% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Bryant, AR.
Comments